<<Back

The Cassie Shipherd Group places Jerry Belle on PDI Board of Directors.

PDI, a provider of commercialization services to the biopharmaceutical industry, announced the appointment of Gerald P. Belle to the Company’s Board of Directors. Mr. Belle’s appointment expands the number of Board members to 10.

Mr. Belle was most recently the Executive Chairman of Merial, Ltd, a global leader in animal health and a joint venture between Merck and Sanofi-Aventis, a position he held for three years until his retirement in 2007. Prior to that, he was President and CEO, North American Pharmaceuticals, Aventis, Inc., until his retirement from that company in 2004, after more than 35 years of service. His experience at Aventis was mainly in executive commercial and general management positions in the United States, Asia, Europe/Middle East/Africa and Canada.

Mr. Belle also serves on the Board of Directors at Myriad Genetics, Inc. He is a graduate of Xavier University in Cincinnati, Ohio, and holds an MBA from Northwestern University in Chicago.

“Jerry has a distinguished career in the pharmaceutical industry and we are very excited that he has chosen to serve on our Board of Directors,” commented John P. Dugan, PDI’s chairman. “We will benefit immensely from his wealth of experience with both large and emerging pharmaceutical companies as we reestablish our leadership in contract sales and support services to this industry.”